MedTrace Logo

Minocycline for the Treatment of Early-Phase Schizophrenia

NCT00733057 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2008-08-12

No results posted yet for this study

Summary

Current antipsychotics have only a limited effect on two core symptoms of schizophrenia, negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline which has a beneficial effect in various neurological disorders. Recent findings in animal models and human case-reports suggest its potential for the treatment of these symptoms of schizophrenia. The current study aims to examine the efficacy of minocycline as add-on treatment for alleviating negative and cognitive symptoms in early-phase schizophrenia. The study will utilize a longitudinal double blind, randomized, placebo-controlled design with patients followed for six-months. Early-phase schizophrenia patients were recruited and randomly allocated to a minocycline or placebo treatment (2:1 ratio; 200 mg/day). The primary outcome measures are the Scale for Assessment of Negative Symptoms (SANS) and assessments of executive functions.

Conditions

  • Negative and Cognitive Symptoms in Schizophrenia

Interventions

DRUG

Minocycline

Minocycline as an add-on drug (200 mg/day)

DRUG

Placebo (200 mg/day)

Sponsors & Collaborators

  • Abarbanel Mental Health Center

    collaborator OTHER_GOV

  • Shalvata Mental Health Center

    lead OTHER

Principal Investigators

  • Yechiel - Levkovitz, M.D. PhD. · Shalvata Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00733057 on ClinicalTrials.gov